306 related articles for article (PubMed ID: 35174566)
1. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
3. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
4. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
[No Abstract] [Full Text] [Related]
5. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
6. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
7. Smaller Differences in the Comparative Effectiveness of Biologics in Reducing Asthma-Related Hospitalizations Compared With Overall Exacerbations.
Akenroye A; Marshall J; Simon AL; Hague C; Costa R; Jamal-Allial A; McMahill-Walraven CN; Haffenreffer K; Han A; Wu AC
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1568-1574.e2. PubMed ID: 38431251
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
9. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
Langton D; Politis J; Collyer T; Khung SW; Bardin P
Respirology; 2023 Dec; 28(12):1117-1125. PubMed ID: 37638723
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.
Bleecker E; Blaiss M; Jacob-Nara J; Huynh L; Guo T; Ye M; Stanford RH; Wang Z; Soler X; Nag A; Nair R; Borsos K
Allergy Asthma Proc; 2024 May; ():. PubMed ID: 38760161
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
13. Comparative Impact of Asthma Biologics: A Nationwide US Claim-Based Analysis.
Al-Shaikhly T; Norris MR; Dennis EH; Liu G; Craig TJ
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1558-1567. PubMed ID: 38423294
[TBL] [Abstract][Full Text] [Related]
14. Precision care in the treatment of pediatric asthma.
Mahmood L; Keskin S; Jefferson AA
Curr Opin Pediatr; 2024 Jun; 36(3):304-309. PubMed ID: 38411592
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
Chen ML; Nopsopon T; Akenroye A
J Allergy Clin Immunol Pract; 2023 May; 11(5):1475-1484.e20. PubMed ID: 36716995
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal Anti-inflammatory Drug (NSAID) Tolerance After Biological Therapy in Patients With NSAID-Exacerbated Respiratory Disease: A Randomized Comparative Trial.
Sánchez J; García E; Lopez JF; Calle A; Buendia JA
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2172-2179. PubMed ID: 37146885
[TBL] [Abstract][Full Text] [Related]
17. A comparison of biologicals in the treatment of adults with severe asthma - real-life experiences.
Kotisalmi E; Hakulinen A; Mäkelä M; Toppila-Salmi S; Kauppi P
Asthma Res Pract; 2020; 6():2. PubMed ID: 32467765
[TBL] [Abstract][Full Text] [Related]
18. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
Kyriakopoulos C; Gogali A; Markozannes G; Kostikas K
Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 38657997
[TBL] [Abstract][Full Text] [Related]
19. Choice of biologics in asthma endotypes.
Wangberg H; Woessner K
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):79-85. PubMed ID: 33306486
[TBL] [Abstract][Full Text] [Related]
20. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database.
Park S; Kim Y; Lee GH; Choi SA
Sci Rep; 2023 Oct; 13(1):17607. PubMed ID: 37848636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
